Cadrenal Therapeutics (CVKD) announced a leadership transition appointing James Ferguson as its new chief medical officer, effective immediately. Ferguson will lead the late-stage clinical development of tecarfarin to include the pivotal trial in LVAD patients and other indications in rare cardiovascular conditions requiring life-long anticoagulation therapy as well as other business development opportunities to build the company’s pipeline. Ferguson replaces Douglas Losordo. Ferguson joins Cadrenal after serving as chief medical officer at Matinas BioPharma (MTNB).